Global Pulse

分类： health

  • Henrietta Lacks: Family of woman whose cells were ‘stolen’ settles second lawsuit

    Henrietta Lacks: Family of woman whose cells were ‘stolen’ settles second lawsuit

    In a landmark resolution addressing one of medical history’s most profound ethical controversies, the descendants of Henrietta Lacks have secured a confidential settlement with Swiss pharmaceutical giant Novartis. This agreement concludes legal allegations that the corporation commercially exploited biological materials obtained without consent from the African American cancer patient in 1951.

    The case centers on what became known as HeLa cells—named using Lacks’ initials—which demonstrated unprecedented biological properties. Unlike typical cell cultures that perish rapidly under laboratory conditions, these specimens exhibited continuous replication capabilities, achieving scientific immortality. This extraordinary characteristic enabled global research laboratories to conduct reproducible experiments using genetically identical cell lines, fundamentally transforming modern medical research.

    Medical historians recognize HeLa cells as instrumental in numerous breakthrough discoveries, including development of the polio vaccine, advanced cancer treatments, HIV research methodologies, and infertility studies. The World Health Organization has acknowledged their indispensable role in twentieth-century medical progress.

    Tragically, the biological miracle emerged from profound personal suffering. Henrietta Lacks, a 31-year-old mother from Baltimore, underwent cervical cancer treatment at Johns Hopkins Hospital where physicians extracted tumor samples without her knowledge or authorization. She succumbed to the disease months later and was interred in an unmarked grave, never comprehending her unintended contribution to science.

    For seven decades, Lacks’ descendants received no financial compensation or recognition while biotech firms generated enormous profits from commercial applications of HeLa cells. This settlement represents the family’s second successful legal action, following a previous confidential agreement with Massachusetts-based Thermo Fisher Scientific Inc. in 2021.

    Prominent civil rights attorney Ben Crump, representing the Lacks family, characterized the resolution as delivering “some measure of justice” that acknowledges Henrietta Lacks’ stolen dignity while recognizing her unwitting contribution to global health advancements. Although specific financial terms remain undisclosed, family representatives expressed satisfaction with the outcome that finally provides tangible recognition after generations of struggle.

    Several parallel lawsuits against additional pharmaceutical companies remain ongoing as the medical community continues grappling with ethical questions surrounding biological material ownership and informed consent protocols.

  • China-SCO Cooperation Center for Metabolic Diseases opens in Shanghai

    China-SCO Cooperation Center for Metabolic Diseases opens in Shanghai

    Shanghai’s Ruijin Hospital has become the hub for a groundbreaking international health initiative with the formal establishment of the China-SCO Cooperation Center for Metabolic Diseases on February 27th. This strategic medical diplomacy effort creates an institutional framework for collaborative research and public health coordination among Shanghai Cooperation Organization member states.

    The newly inaugurated center will leverage Ruijin Hospital’s renowned clinical expertise and research capabilities in metabolic disorders to establish a multinational platform addressing the growing global burden of conditions such as diabetes, obesity, and cardiovascular diseases. The initiative represents a significant advancement in cross-border medical cooperation within the SCO region.

    This multilateral health partnership aims to facilitate knowledge exchange, develop standardized prevention protocols, and accelerate innovative treatment methodologies across participating nations. By pooling resources and expertise, the center seeks to establish comprehensive metabolic disease surveillance systems and implement evidence-based intervention strategies tailored to diverse populations within the SCO community.

    The establishment of this specialized medical center underscores China’s evolving role in global health governance and demonstrates the practical implementation of the Health Silk Road concept. It marks a substantial commitment to addressing non-communicable diseases through international cooperation, potentially serving as a model for future multinational healthcare initiatives across Eurasia and beyond.

  • South Africa starts mass cattle vaccination program to halt foot-and-mouth outbreak

    South Africa starts mass cattle vaccination program to halt foot-and-mouth outbreak

    HEIDELBERG, South Africa — South African authorities initiated a massive emergency vaccination campaign for cattle on Friday in response to a devastating foot-and-mouth disease outbreak that has rapidly spread throughout the nation’s livestock sector, threatening food security and export economies.

    The escalating biological crisis, which began intensifying in late 2022, has already infected over 297,000 cattle and necessitated the culling of more than 120,000 animals as containment measures. The outbreak has triggered international trade restrictions from key importers including China and Zambia, potentially causing massive meat shortages, widespread job losses, and millions in lost agricultural revenue.

    Agriculture Minister John Steenhuisen formally launched the national vaccination drive using an initial shipment of one million vaccines recently acquired from Turkey. Additional doses are anticipated to arrive this weekend, though concerns persist that current supplies remain substantially inadequate for the estimated 12 million cattle requiring immunization.

    “Our definitive strategy involves mass vaccination to proactively manage foot-and-mouth disease nationwide,” Steenhuisen stated. “This approach enables outbreak prevention rather than reactive containment measures.”

    The coastal province of KwaZulu-Natal has emerged as the epidemic’s epicenter with over 17,000 affected farms. The government has officially declared the situation a national disaster, activating legal provisions for emergency funding allocation primarily directed toward vaccine procurement.

    The national treasury has committed approximately $25 million to combat the outbreak, with the majority designated for vaccination purposes. Agricultural producers face mounting challenges as they quarantine infected livestock, suspend trading operations, and manage critical vaccine shortages.

    Dr. Dirk Verwoerd, veterinarian at South Africa’s largest meat producer Karan Beef, described the outbreak as “completely out of control” with rampant infections occurring daily across all provinces. The company’s Heidelberg facility—the nation’s largest feedlot spanning 2,300 hectares with capacity for 140,000 cattle—illustrates the industry’s vulnerability.

    “The damage permeates entire supply chains,” Verwoerd explained. “Primary producers cannot sell livestock, processors cannot purchase animals, slaughter operations halt, and ultimately consumers bear the economic consequences. Our immediate objective must be achieving stability through national herd vaccination.”

  • New sleeping sickness pill gets nod, paving the way for use in Africa

    New sleeping sickness pill gets nod, paving the way for use in Africa

    In a landmark decision poised to transform the fight against sleeping sickness, European drug regulators have officially endorsed a revolutionary single-dose treatment that could accelerate elimination efforts for the parasitic disease. The European Medicines Agency’s committee granted approval to acoziborole, developed by pharmaceutical giant Sanofi, marking a critical advancement in treating this neglected tropical disease predominantly affecting sub-Saharan Africa.

    The newly approved therapy represents a dramatic improvement over existing regimens that require complex 10-day hospital treatments and invasive spinal taps. Acoziborole’s three-pill, single-dose administration offers unprecedented accessibility for remote communities where the disease thrives. This simplified treatment protocol eliminates the need for spinal fluid analysis to determine infection stage, making widespread implementation feasible even in resource-limited settings.

    Sleeping sickness, scientifically known as human African trypanosomiasis, is transmitted through tsetse fly bites in rural Africa. The parasite causes neurological deterioration characterized by inverted sleep cycles, progressing to coma and death if untreated. Historically, treatments involved toxic medications and complex hospital stays, creating significant barriers for patients in isolated regions.

    Recent decades have witnessed remarkable progress against the disease, with reported cases dropping from over 10,000 in 2009 to fewer than 600 in 2024 for the most common strain. This decline stems from improved treatments developed in the early 2000s and sustained control efforts. The World Health Organization has established an ambitious target to halt transmission by 2030.

    Medical experts highlight the drug’s potential significance in the elimination campaign. Dr. Junior Matangila of the Drugs for Neglected Diseases initiative noted that ‘this disease is on the brink of elimination’ and that the new treatment could substantially accelerate progress. The development is particularly noteworthy as elimination might be achieved without a vaccine—a rare accomplishment in infectious disease control.

    However, researchers caution that challenges remain. Dr. Monica Mugnier of Johns Hopkins University acknowledged the treatment as a major improvement while emphasizing ongoing uncertainties about parasite reservoirs and undiagnosed cases. Sanofi has committed to donating doses to the WHO, ensuring the treatment reaches patients free of charge, with initial implementation expected in Congo before expanding to other affected nations.

  • Australian comedian Magda Szubanski in remission from cancer

    Australian comedian Magda Szubanski in remission from cancer

    Beloved Australian entertainer Magda Szubanski has shared a significant health update, revealing she has achieved remission following treatment for an aggressive form of cancer. The acclaimed comedian, celebrated for her iconic portrayal of Sharon Strzelecki in the hit series Kath & Kim, disclosed her stage four Mantle cell lymphoma diagnosis in May 2023.

    Szubanski conveyed her positive news through social media channels on Friday, announcing the successful completion of her chemotherapy regimen. “Seems I’m not dead… So, phew, big relief,” the 64-year-old actress wrote with characteristic humor. While acknowledging the remission doesn’t constitute a full cure, she expressed optimism that the treatment outcome would “keep the cancer at bay for a good long time.”

    Mantle cell lymphoma represents a rare and rapidly progressing blood cancer that demands aggressive treatment approaches. Szubanski’s diagnosis last year prompted an overwhelming show of support from both fans and fellow celebrities, including internationally renowned artists Kylie Minogue and Toni Collette.

    Beyond her entertainment career spanning beloved films like Babe and Happy Feet, Szubanski has been a prominent advocate for social causes, most notably her campaigning for marriage equality in Australia. The Logie Hall of Fame inductee remains one of Australia’s most cherished comedic talents, with her health journey being followed by admirers nationwide.

  • Major hospital investigates deadly fungus cluster after two transplant patients die, four left seriously ill

    Major hospital investigates deadly fungus cluster after two transplant patients die, four left seriously ill

    A major public health investigation is underway in Sydney after a cluster of rare fungal infections, linked to hospital construction activity, resulted in two patient fatalities and four serious illnesses. The outbreak occurred within the transplant unit of the Royal Prince Alfred (RPA) Hospital in Camperdown between October and December of last year.

    The causative agent has been identified as Aspergillus, a common mold typically found in soil, plants, and damp environments. Health experts indicate that construction work and excavation on the hospital’s grounds likely disturbed deposits of the mold, releasing its spores into the air. While generally harmless to the general public, Aspergillus poses a severe threat to immunocompromised individuals, particularly transplant recipients whose immune systems are deliberately suppressed.

    Upon detecting an unexpected surge in infections, hospital infectious disease clinicians initiated an immediate response. As a precautionary measure, all patients were evacuated from the transplant ward and relocated while a specialized remediation team executed an intensive deep cleaning protocol. Concurrently, significant upgrades were implemented for the ward’s air filtration systems, with subsequent air quality tests confirming the successful reduction of Aspergillus to safe levels.

    The Sydney Local Health District has extended its deepest condolences to the families of the deceased patients. Hospital authorities proactively notified other vulnerable patients who had been on the ward; however, no additional cases have been reported. Some high-risk individuals were administered antifungal medication as a preventive measure.

    NSW Chief Health Officer Dr. Kerry Chant, leading an advisory panel, has since certified the ward as safe for reopening. The investigation continues to focus on the precise transmission pathway, with NSW Health pledging to collaborate with construction contractors to implement any recommended safety measures. The incident has cast a spotlight on the RPA Hospital’s ongoing $940 million redevelopment project, which is situated near the transplant unit and is scheduled to continue until 2029.

  • Initial online pediatric consultations offered

    Initial online pediatric consultations offered

    Beijing has initiated a pioneering healthcare program that authorizes first-time virtual medical consultations for pediatric patients, signaling a transformative shift in China’s digital healthcare landscape. The National Health Commission approved this innovative pilot project, which effectively overturns existing regulations that previously limited online medical services exclusively to follow-up appointments after initial in-person visits.

    The year-long trial program will be implemented through two of Beijing’s premier pediatric institutions—Beijing Children’s Hospital and the Capital Institute of Pediatrics, both operating under the affiliation of Capital Medical University. These facilities will provide initial remote consultations across three specialized domains: child growth and development, pediatric nutrition, and childhood dermatological conditions.

    According to official statements from the Beijing Municipal Health Commission, the telemedicine services became accessible starting January 31 through the hospitals’ dedicated WeChat platforms. The comprehensive digital healthcare package includes preliminary online assessments, virtual diagnostic consultations, and home delivery services for prescribed medications.

    This strategic initiative addresses the significant challenge of geographical healthcare disparities, particularly relevant given Beijing’s status as a medical hub that attracts substantial numbers of patients from across China. The commission emphasized that internet-based medical services effectively eliminate geographical barriers while providing convenient access to specialized care.

    The selection criteria for participating hospitals incorporated multiple factors including institutional management capabilities, prior experience with virtual follow-up consultations, the volume and profile of non-local patients, and overall physician service capacity. The three designated specialties were specifically chosen due to their high proportion of out-of-town patients and relatively manageable diagnostic risks associated with remote assessment.

    Participating physicians must meet rigorous qualification standards, including minimum three years of independent clinical experience, the professional rank of attending physician or higher, and at least one year of prior teleconsultation experience. Additional requirements include demonstrated communication proficiency, completion of specialized digital healthcare training, and successful passage of competency assessments.

    The regulatory framework mandates that a guardian must be present during all pediatric teleconsultations. Physicians are instructed to immediately terminate virtual sessions and recommend in-person visits if a child’s condition appears unsuitable for remote diagnosis. Health authorities will maintain strengthened supervision throughout the pilot program, with particular attention to medical quality, patient safety, and cybersecurity protocols.

    This development aligns with China’s rapidly expanding digital healthcare infrastructure, which recorded 130 million online medical consultations during 2024 across 3,756 internet hospitals nationwide. The National Healthcare Security Administration had previously announced in January 2025 the establishment of pricing guidelines for initial online consultations, indicating systematic preparation for broader implementation of telemedicine services.

  • India inspects 90% of cough syrup makers, finds lapses in some

    India inspects 90% of cough syrup makers, finds lapses in some

    India’s pharmaceutical regulatory authority has completed sweeping inspections of approximately 90% of the nation’s cough syrup manufacturers, revealing significant compliance failures across multiple facilities. The comprehensive audit comes in response to a series of international tragedies linking Indian-made syrups to the deaths of over 140 children across Africa and Central Asia since 2022.

    Drugs Controller General of India Rajeev Raghuvanshi announced the findings at the IPA 11th Global Pharmaceutical Quality Summit in Mumbai, confirming that nearly 1,100 manufacturers had undergone rigorous evaluation. The inspections identified critical violations including breaches of good manufacturing practices, failure to test incoming raw materials, and implementation of invalid methods and processes.

    The regulatory crackdown follows the October discovery of diethylene glycol contamination in Coldrif cough syrup manufactured by Sresan Pharmaceutical, which resulted in 24 pediatric fatalities. This incident has placed unprecedented pressure on India’s $42 billion pharmaceutical industry, challenging its reputation as the ‘pharmacy of the world’.

    Raghuvanshi stated, ‘We took serious actions on serious non-compliances, and our belief is that the rot of cough syrup manufacturing will be removed.’ While declining to specify the exact number of non-compliant companies or identify them publicly, the regulator confirmed additional protective inspections of 1,250 drug manufacturing units to evaluate potential risks.

    Concurrently, India’s drug regulatory agency is undertaking transformative reforms to achieve parity with US Food and Drug Administration standards. The modernization initiative includes creating 1,500 new positions—40% through flexible contract roles—and potentially engaging global industry experts as advisors. The regulator is also piloting artificial intelligence applications to streamline application reviews and has eliminated redundant export clearance requirements for shipments to the US, Europe, Australia, Japan, the UK and Canada.

  • Thai officials say 72 tigers at tourist parks died of canine distemper, allaying bird flu fears

    Thai officials say 72 tigers at tourist parks died of canine distemper, allaying bird flu fears

    Thai health authorities have confirmed that the sudden deaths of 72 tigers at two northern Thailand animal parks resulted from canine distemper virus (CDV) infection, explicitly ruling out any connection to avian influenza. The fatalities occurred within a concentrated 10-day period between February 8-18 at Tiger Kingdom facilities in Chiang Mai province’s Mae Taeng and Mae Rim districts.

    Public Health Minister Pattana Promphat addressed concerns at a Tuesday press conference, emphasizing that the CDV pathogen presents no known transmission risk to humans. ‘There has not been an animal-to-human infection case,’ Minister Promphat stated, while acknowledging ongoing health monitoring of individuals with recent animal contact.

    Veterinary investigations revealed the presence of CDV genetic material and secondary bacterial infections in necropsy results, with no detected traces of avian influenza viruses. Officials noted that confined big cats face heightened vulnerability to such infections due to stress factors and genetic limitations from inbreeding practices.

    Despite official reassurances, participating veterinarian Visit Arsaithamkul raised concerns about undetermined infection origins. Through social media channels, Dr. Arsaithamkul suggested possible contamination through shared food sources between the geographically proximate facilities.

    All deceased tigers underwent controlled cremation and burial procedures following thorough disinfection protocols to prevent further disease spread. Both affected parks remain temporarily closed as investigations continue.

    Health authorities maintain nationwide vigilance against potential avian influenza threats, with Disease Control Department Director-General Monthien Khanasawat advising cautious poultry consumption practices following recent regional bird flu cases.

  • Ramadan ‘crash’? Why UAE residents get headaches, fatigue in first week of fasting

    Ramadan ‘crash’? Why UAE residents get headaches, fatigue in first week of fasting

    As Ramadan commences across the United Arab Emirates, healthcare professionals are observing a predictable pattern of physiological adaptation among fasting residents. Many individuals report experiencing pronounced headaches, persistent fatigue, and diminished energy levels during the initial week of fasting, particularly in the hours preceding iftar.

    Medical experts attribute these symptoms to the body’s complex adjustment to altered nutritional intake, hydration patterns, and sleep cycles. Dr. Archana Purushothaman, an endocrinology and metabolism specialist at Fakeeh University Hospital Dubai, explains: “During the first days of Ramadan, the body undergoes significant metabolic recalibration. Blood glucose levels progressively decrease, insulin secretion patterns shift, and mild dehydration frequently develops. Simultaneously, hormonal regulators of energy must establish new rhythmic patterns.”

    This temporary biochemical imbalance manifests most noticeably during late afternoon hours when the body’s glycogen reserves become depleted. Clinical dietitian Swapna Mary John of International Modern Hospital Dubai emphasizes that dehydration plays a more substantial role than commonly recognized: “Thirst represents a delayed indicator of dehydration. Even moderate fluid loss can impair cerebral blood flow and muscular function, resulting in cephalalgia, reduced vitality, and concentration difficulties.”

    The phenomenon, colloquially termed ‘Ramadan crash’ by residents, proves particularly challenging for habitual caffeine consumers experiencing withdrawal symptoms. Salim S., a Dubai resident, describes his experience: “I initiate each day feeling normal, but by mid-afternoon, I develop debilitating cephalgia and diminished focus. The only recourse often involves resting until iftar.”

    Nutritional choices significantly influence energy sustainability throughout the fasting period. Experts identify common suhoor misconceptions, including overreliance on refined carbohydrates and sugary items that provoke rapid glycemic fluctuations. Conversely, healthcare professionals recommend incorporating complex carbohydrates, lean proteins, and healthy fats during pre-dawn meals to stabilize metabolic parameters.

    Hydration management represents another critical consideration. Rather than consuming large volumes simultaneously, medical advisors suggest gradual fluid intake between iftar and suhoor, complemented by moisture-rich foods like fruits and soups. These strategies collectively help mitigate the adaptation challenges associated with Ramadan’s initial phase while honoring religious traditions.